Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: M. Ramle who wrote (842)	5/6/1998 1:09:00 AM
From: John Metcalf	Read Replies (1) \| Respond to of 10280

Granted, ENMD bounced way too high for a company with only pre-clinical murine results. However, at maximum apogee, Entremed only reached a little over $1 billion in market cap. SEPR has been at the $1.4B mark for some time on primary share value; add a couple hundred million more fully diluted. The long-term rise in the stock and relative stability of the price suggests that institutions (and individuals) are buying and holding it. Sepracor is a very unusual candidate for trading -:) In regard to selling covered calls, I can't see how sixty cents premium is a valid reward for the risk that news, a Lilly deal for example, or Levalbuterol approval, or another patent, could come at any time.